Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis.

@article{Nearchou2015AcquiredHA,
  title={Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis.},
  author={Andreas D. Nearchou and Antonis Valachis and P. A. R. M. Lind and Olof Akre and Per Sandstr{\"o}m},
  journal={Clinical genitourinary cancer},
  year={2015},
  volume={13 4},
  pages={
          280-286
        }
}
Hypothyroidism in patients with metastatic renal cell carcinoma (mRCC) during treatment with the tyrosine kinase inhibitors (TKIs) sunitinib and sorafenib is a well-established side effect. Furthermore, the potential role of hypothyroidism as predictive marker of outcome has been studied but with conflicting results. The aim of the present meta-analysis was to assess the predictive value of hypothyroidism for progression-free (PFS) and overall survival (OS) in patients with mRCC during TKI… CONTINUE READING

Similar Papers

Loading similar papers…